Dailypharm Live Search Close

VUNO knocks on the U.S. market to generate operating profit

By Hwang, Byung-woo | translator Kang, Shin-Kook

24.08.01 05:00:13

가나다라 0
Generated the highest sales last year in the company's history, yet its operating profit and net profit indicators are negative

Expects to generate stable domestic sales with the 'New Health Technology Assessment System'

After officially launching the product, showcased at AAIC, in the U.S. market on July 28th, VUNO will focus on expanding its sales network

Medical artificial intelligence (AI) company VUNO has launched an AI-based brain quantification device in the United States market. Whether the company will use this as a stepping stone for sales expansion garners attention.

VUNO's strategy is to quickly turn around by increasing the sales performance of its major product and entering the overseas market. At the same time, improving negative indicators for operating profit and net profit would take time.

 ▲VUNO officially launched its product to the U.S. market on July 28th, seeking to expand sales.


VUNO's consolidation sales last year were KRW 13.3 billion, the highest sales in the company's history. The company achieved a 60% increase from the sales of KRW 8.2 billion in 2022.

Quarterly report also showed an increasi

Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)